Press Releases

Date Title and Summary Additional Formats
Toggle Summary Chemical Genomics – CALBIOsummit 2002 April 21,22,23
(BW Healthwire)–April 18, 2002—Xencor’s President and CEO, Dr. Bassil Dahiyat Chairs Panel at CALBIOsummit 2002
View HTML
Toggle Summary Xencor Licenses Patent For Chemical Genomics Technology Profiling Biological And Pharmacological Interactions
(BW Healthwire)–March 11, 2002—Xencor President and CEO Presents at SG Cowen Health Care Conference Today at 10:00 am EST
View HTML
Toggle Summary Xencor Expands Protein Optimization Technology To Develop Next-Generation Biotechnology Products
Xencor Expands Protein Optimization Technology To Develop Next-Generation Biotechnology Products (BW Healthwire)–February 20, 2002—Monrovia, CA – February 20, 2002 – Xencor today announced that it has signed licensing agreements with the California Institute of Technology and Pennsylvania State
View HTML
Toggle Summary Syngenta’s Torrey Mesa Research Institute And Xencor Sign Research And License Agreement
Syngenta’s Torrey Mesa Research Institute And Xencor Sign Research And License Agreement (BW Healthwire)–January 03, 2002—La Jolla, CA and Monrovia, CA.- January 3, 2002 -Torrey Mesa Research Institute (TMRI), a wholly owned subsidiary of Syngenta (NYSE: SYT), today announced the signing of a three
View HTML
Toggle Summary Xencor Expands Management Team To Lead Drug Discovery And Protein Optimization Programs
Xencor Expands Management Team To Lead Drug Discovery And Protein Optimization Programs (BW Healthwire)–October 09, 2001—Xencor today announced that Stephen K. Doberstein, Ph.D. has joined as Vice President, Chemical Biology and Robert E. Pacifici, Ph.D.
View HTML
Toggle Summary Xencor Receives Two Patents For Ultra-Fast Optimization Technology To Create A New Generation Of Biotechnology Products
Xencor Receives Two Patents For Ultra-Fast Optimization Technology To Create A New Generation Of Biotechnology Products Xencor Receives Two Patents For Ultra-Fast Optimization Technology To Create A New Generation Of Biotechnology Products (BW Healthwire)–August 06, 2001—Protein Design Automation™
View HTML
Toggle Summary Xencor Receives SBIR Phase II Grant for High Throughput Screening of Novel Computationally Derived Optimized Proteins
Xencor Receives SBIR Phase II Grant for High Throughput Screening of Novel Computationally Derived Optimized Proteins (BW Healthwire)–June 19, 2001—Paves the Way for Improved Biopharmaceuticals and New Industrial and Agricultural Products Xencor today announced that the company has been awarded a
View HTML
Toggle Summary Xencor Expands Management Team; Leverages $50 Million Series C Financing to Fuel Development Efforts
Xencor Expands Management Team; Leverages $50 Million Series C Financing to Fuel Development Efforts (BW Healthwire)–July 19, 2001—Xencor today announced that E.William Radany, Ph.D. has joined the company as Chief Business Officer and Joyce L. Morrison has joined as Vice President, Intellectual
View HTML
Toggle Summary Xencor Closes $12.3 Million in Financing
Xencor Closes $12.3 Million in Financing (BW Healthwire)–June 14, 1999—Xencor Inc. announced the closing of a second round of private equity financing for $12.3 million. This financing was led by Stafford Investments LLC of Chicago, Illinois and will be used to accelerate the research, development
View HTML
Toggle Summary Xencor Co-Founder, Stephen Mayo, Presents Protein Design Automation Results at AAAS Meeting
Xencor Co-Founder, Stephen Mayo, Presents Protein Design Automation Results at AAAS Meeting (BW Healthwire)–January 25, 1999—Stephen Mayo Ph.D., Associate Professor of Biology, California Institute of Technology and co-founder of Xencor Inc., presented new results from Protein Design AutomationTM,
View HTML